Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Onbrez

- PMLiVE

Novartis announces departures of three execs

Follows deals to sell divisions to GSK and Lilly

- PMLiVE

Novartis’ Bexsero triumphs at UK Prix Galien

The Awards also saw Janssen's Sirturo pick up the Orphan Drug prize

- PMLiVE

Boehringer Ingelheim promotes Debraj Dasgupta

He will lead on its global marketing and sales platforms

- PMLiVE

Novartis expands eyecare partnership with NHS

And wins new licence for Lucentis

- PMLiVE

Avastin safe in eye disease, says Cochrane

Recommends off-label use of Roche drug as cheaper alternative to Novartis’ Lucentis

- PMLiVE

Mixed messages for AZ’s benralizumab in COPD study

Respiratory hope misses primary goal in trial data presented at ERS congress

- PMLiVE

Boehringer’s Spiriva cleared for asthma in EU

Drug approved as a treatment for adults with severe asthma

- PMLiVE

Pharma and med tech companies form eye health group

The Industry Vision Group wants the NHS to make eye care a priority

Novartis building

Novartis’ Ultibro tops Seretide in comparative COPD trial

Will help Novartis position Ultibro as a corticosteroid-free alternative to GSK's blockbuster

Novartis building

Novartis heart failure trial leads the buzz at ESC

Potential blockbuster LCZ696 cuts cardiovascular deaths by 20% versus standard therapy

Novartis building

Novartis licenses tuberculosis R&D to TB Alliance

Includes drugs to tackle resistant forms of the disease

- PMLiVE

Eisai ‘outraged’ by IQWIG’s failure to back epilepsy drug

German cost-effectiveness body once again says Fycompa should not be reimbursed

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links